• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Craig Samitt Is Leaving Blue Cross and Blue Shield of Minnesota

Article

Samitt announced he is retiring after three years at the helm of the Minnesota Blues plan.

Craig Samitt, M.D., MBA, the president and CEO of Blue Cross and Blue Shield of Minnesota, who has talked often about transforming healthcare, is retiring from the nonprofit insurer.

In a LinkedIn post today, Samitt said he was retiring as of May 3 after much soul searching.

Craig Samitt

Craig Samitt

I couldn’t be prouder of the innovative partnerships we forged with providers, the transformed culture we built, the steps we took to speak out and stand up for what is right, and the progress we’ve made in showing the impact an ‘un-health plan’ can have in driving meaningful industry change,” the post says.

The Star Tribune and other outlets reported that Kathleen Blatz, former chief justice of the Minnesota Supreme Court, will act as interim CEO of the Minnesota Blues plan starting tomorrow. She also filled in as the company's interim president and CEO before Samitt took charge of the company in July 2018.

Related:Healthcare hits “Double Peak”

Unlike many guarded healthcare insurance executives, Samitt gives many interviews, speaking volubly about value-based care, putting more emphasis on prevention and, more recently, about racism and inequity.

“We’ve been in the sickness business, but if we were to invest in the ounce (of prevention) I would argue that racial injustice, social disparity, SDOH, along with many of the other things that we would do to prevent, protect and avoid illness would make us a healthier society, “he said in an interview with HealthLeaders in January.

Related: Minnesota Blues CEO Craig Samitt on COVID-19, 2021 Rates Increases, Telehealth, Medicare for all, and WFH

The Star Tribune reported today that in May 2020, Moody's Investors Service revised its outlook on Minnesota Blues plans, moving it up to stable from negative but downgraded its financial strength and debt ratings based on declines in membership and weak EBITDA margins.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Related Content
© 2024 MJH Life Sciences

All rights reserved.